CD44 and neoplasm: Using gene expression profiling of ALDH+ and CD24-CD44+ BCSCs (comparing to bulk tumor cells) isolated across different subtypes of human breast cancer tissues together with multi-marker immunofluorescence including CD24, CD44 and ALDH1, we have recently shown that the CD24-CD44+ and ALDH+ cell populations identify anatomically distinct breast CSCs with distinct EMT (epithelial-to-mesenchymal transition) and MET (mesenchymal-to-epithelial transition) gene-expression profiles respectively [8].